Acute myeloid leukaemia trials in China

In China 226 Also abroad 763

226 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 2Not yet taking people in China
Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT
Where
Shanghai
Age
18 years to 75 years
People
73
Run by
Ruijin Hospital
See details and how to joinNCT06765928
Phase 4Not yet taking people in China
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
Where
Guangzhou
Age
18 years to 65 years
People
172
Run by
Nanfang Hospital, Southern Medical University
See details and how to joinNCT06763666
Early phase 1Taking people
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Where
Suzhou
Age
18 years to 70 years
People
7
Run by
Hrain Biotechnology Co., Ltd.
See details and how to joinNCT06760260
Early phase 1Taking people
A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
Where
Hangzhou
Age
18 years and over
People
27
Run by
Zhejiang University
See details and how to joinNCT06762132
No phaseNot yet taking people in China
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia
Where
Chengdu, Jinan, Shijiazhuang, Zhengzhou
Age
18 years and over
People
358
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06643195
Phase 2Taking people
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
Where
Beijing
Age
18 years to 75 years
People
20
Run by
Beijing 302 Hospital
See details and how to joinNCT06741722
Phase 1/2Taking people
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
Where
Suzhou
Age
18 years and over
People
135
Run by
Chen Suning
See details and how to joinNCT06746519
Early phase 1Not yet taking people in China
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
Where
Guangzhou
Age
18 years to 80 years
People
10
Run by
Guangzhou Ruixin Biotechnological Co., LTD
See details and how to joinNCT06702098
Phase 1/2Taking people
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
Where
Beijing
Age
6 years to 90 years
People
85
Run by
Essen Biotech
See details and how to joinNCT06420063
No phaseTaking people
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
Where
Nantong
Age
18 years to 70 years
People
83
Run by
Affiliated Hospital of Nantong University
See details and how to joinNCT06643962
Phase 2Not yet taking people in China
Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Where
Shanghai
Age
18 years to 59 years
People
218
Run by
Ruijin Hospital
See details and how to joinNCT06652685
Early phase 1Taking people
EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia
Where
Hefei
Age
18 years to 70 years
People
9
Run by
Zhimin Zhai
See details and how to joinNCT06642025
Phase 2Taking people
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
Where
Hangzhou
Age
60 years to 70 years
People
42
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT06621199
Phase 3Not yet taking people in China
Twice-per-weekSelinexor, 2 Days Melphalan
Where
Chengdu, Jinan, Shijiazhuang, Zhengzhou
Age
55 years and over
People
126
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06613035
Phase 4Taking people
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Where
Hangzhou
Age
60 years to 75 years
People
118
Run by
He Huang
See details and how to joinNCT06571825
Phase 2Taking people
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Where
Beijing, Changsha, Guangzhou, Hefei, Jinan, Kaifeng, Nanning, Shanghai, Suzhou, Xuzhou, Zhengzhou
Age
Up to 18 years
People
500
Run by
Children's Hospital of Soochow University
See details and how to joinNCT06221683
Phase 2Taking people
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Where
Changsha, Guangzhou, Hefei, Jinan, Kaifeng, Nanning, Shanghai, Suzhou, Xuzhou, Zhengzhou
Age
Up to 18 years
People
50
Run by
Children's Hospital of Soochow University
See details and how to joinNCT06316960
Phase 2Not yet taking people in China
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
Where
Beijing
Age
18 years and over
People
85
Run by
Navy General Hospital, Beijing
See details and how to joinNCT06470841
Early phase 1Not yet taking people in China
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
Where
Suzhou
Age
18 years to 70 years
People
20
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT06559644
Phase 1Taking people
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
Where
Beijing, Chengdu, Harbin, Shanghai, Shijiazhuang, Tianjin
Age
18 years and over
People
100
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT06550713
Phase 2/3Enrolling by invitation
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
Where
Suzhou
People
98
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT06544109
Phase 2Taking people
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Where
Beijing
Age
18 years to 70 years
People
67
Run by
Beijing 302 Hospital
See details and how to joinNCT06536959
No phaseTaking people
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
Where
Huai'an
Age
18 years to 75 years
People
50
Run by
Yang Xiaotian
See details and how to joinNCT06536010
No phaseTaking people
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
Where
Shanghai
Age
18 years to 55 years
People
50
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT06111612
No phaseTaking people
MRD Response-adapted Allo-HSCT for Adverse-risk AML
Where
Beijing
Age
16 years to 65 years
People
178
Run by
Peking University People's Hospital
See details and how to joinNCT06301425